This is the authors' abstract. We don't add key points for this paper.
We have demonstrated specific binding sites for [125I]glucagon-like peptide 1 (GLP-1) on membranes from the rodent thyrotrope cell line, alpha-TSH. Specific [125I]GLP-1 binding was saturable and time dependent. Equilibrium saturation binding analysis was consistent with the presence of a single class of binding site (binding capacity, 85 +/- 7 fmol/mg protein) with a dissociation constant (Kd) of 28 +/- 13 pM. The specific GLP-1 receptor agonists, exendin-4 and exendin-3, and the antagonist, exendin-(9-39), bound to the receptor sites with high affinity (Ki = 190 +/- 70 pM; 130 +/- 50 and 1200 +/- 470 pM, respectively). Chemical cross-linking of [125I]GLP-1-receptor complexes revealed a single band of 64,300 +/- 100 Mr in alpha-TSH membranes. In addition, specific PCR studies demonstrated the presence of GLP-1 receptor messenger RNA. Binding of the peptide to alpha-TSH cell membranes resulted in increased intracellular cAMP concentrations (10 nM GLP-1, 1010 +/- 83 pmol/10(6) cells.h; control, 175 +/- 60 pmol/10(6) cells.h; P < 0.002), indicating that the receptor is linked to stimulation of adenylyl cyclase. GLP-1-mediated increases in cAMP were inhibited by exendin-(9-39) in a dose-dependent manner. Furthermore, GLP-1 stimulates basal TSH release from dispersed anterior pituitary cells in a concentration-dependent manner (100 nM GLP-1, 63 +/- 3 fmol/10(6) cells.h; control, 35 +/- 1 fmol/10(6) cells.h; P < 0.0005), but had no effect on basal PRL, GH, or LH release.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Beak et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: